
Arynta
Lisdexamfetamine Dimesylate Oral
- SKU
- 24338-019
- UPC
- 0324338019016
- Mfr
- Azurity Pharmaceuticals, Inc.
100 ml in 1 bottle, 1 bottle in 1 carton
$1,100.00
Price for one pack
Controlled medicine — prescription required. Upload your prescription at checkout or email it to us after ordering. We ship once a pharmacist has checked it and confirmed it with your prescriber. How it works
2 )] . ARYNTA is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events.
- Strength
- Lisdexamfetamine Dimesylate 10 mg/mL
- Unit of measure
- Per mL
- Dosage form
- Solution
- Route
- Oral
Pharmacologic class
- Central Nervous System StimulantEstablished class
- Central Nervous System StimulationPhysiologic effect
- Brand name
- Arynta
- Generic name
- Lisdexamfetamine Dimesylate Oral
- Manufacturer
- Azurity Pharmaceuticals, Inc.
- Product NDC (SKU)
- 24338-019
- UPC
- 0324338019016, 0324338103012, 0324338109014, 0324338160015
- Active ingredients
- Lisdexamfetamine Dimesylate 10 mg/mL
- Unit of measure
- Per mL
- Dosage form
- Solution
- Route
- Oral
- DEA schedule
- CII
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- NDA
- Application number
- NDA219847
- Marketed since
- March 20, 2026
- Label revised
- July 30, 2025
| Package NDC | Description |
|---|---|
| 24338-019-01 | 1 BOTTLE in 1 CARTON (24338-019-01) / 100 mL in 1 BOTTLE |
Reading this NDC
24338-019-01
- 01Labeler code
- Azurity Pharmaceuticals, Inc.
- 02Product code
- Arynta, solution
- 03Package code
- 1 bottle in 1 carton (24338-019-01) / 100 ml in 1 bottle
Lisdexamfetamine is a prodrug of dextroamphetamine. Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD and BED is not known.
Warning: Abuse, misuse, and addiction
ARYNTA has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including ARYNTA, can result in overdose and death, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing ARYNTA, assess each patient's risk for abuse, misuse, and addiction.
Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout ARYNTA treatment, reassess each patient's risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction. WARNING: ABUSE, MISUSE, AND ADDICTION See full prescribing information for complete boxed warning.
ARYNTA has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including ARYNTA, can result in overdose and death:
- Before prescribing ARYNTA, assess each patient's risk for abuse, misuse, and addiction.
- Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug.
- Throughout treatment, reassess each patient's risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.
ARYNTA is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older Moderate to severe binge eating disorder (BED) in adults. Limitations of Use: The use of ARYNTA is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.
ARYNTA is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of ARYNTA for the treatment of obesity have not been established. ARYNTA is a central nervous system (CNS) stimulant indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.
Moderate to severe binge eating disorder (BED) in adults Limitations of Use: The use of ARYNTA is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage
ARYNTA is not indicated for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of ARYNTA for the treatment of obesity have not been established
Read before you order

ADHD · 2 min read
ADHD medication: stimulants vs non-stimulants
How methylphenidate, amphetamines, lisdexamfetamine, atomoxetine, guanfacine and viloxazine work, and how doctors choose between them.

ADHD · 2 min read
Living with ADHD medication side effects
Practical ways to handle reduced appetite, poor sleep and the afternoon crash on ADHD medicine, and when to call your doctor.

ADHD · 2 min read
ADHD medication in adults: what is different
Adult ADHD is often diagnosed late. Here is how treatment works for adults, including heart checks, interactions and alcohol.
More in ADHD
View all
Brand · Capsule
Adderall XR
Dextroamphetamine Sulfate 1.25 mg/1, Dextroamphetamine Saccharate 1.25 mg/1, Amphetamine Aspartate Monohydrate 1.25 mg/1, Amphetamine Sulfate 1.25 mg/1
- SKU
- 54092-381
- Mfr
- Takeda Pharmaceuticals America, Inc.
From $922.99Prescription required

Generic · Capsule
Atomoxetine
Atomoxetine Hydrochloride 40 mg/1
- SKU
- 0904-6908
- Mfr
- Major Pharmaceuticals
From $18.99Min. 16 packs

Generic · Capsule
Atomoxetine
Atomoxetine Hydrochloride 40 mg/1
- SKU
- 71335-3033
- Mfr
- Bryant Ranch Prepack
From $18.99Min. 16 packs

Brand · Solution
Atoncy
Atomoxetine Hydrochloride 4 mg/mL
- SKU
- 30698-456
- Mfr
- Validus Pharmaceuticals LLC
From $205.06Min. 2 packs